参蛤平喘胶囊对老年晚期非小细胞肺癌合并COPD患者肺功能、血清T细胞亚群及免疫球蛋白的影响

目的探讨参蛤平喘胶囊对老年晚期非小细胞肺癌(NSCLC)合并慢性阻塞性肺疾病(COPD)患者肺功能、血清T细胞亚群及免疫球蛋白的影响。方法利用随机数字表法将2014年1月~2016年1月我院收治的114例老年晚期NSCLC合并COPD患者平均分为观察组和对照组,每组57例。对照组患者均给予吸氧、扩张支气管及GP方案化疗等常规治疗,观察组在对照组治疗基础上同时给予参蛤平喘胶囊进行治疗。治疗后,评价各组治疗效果;治疗前后,分别检测各组患者的肺一氧化碳弥散量(DLCO)、第1 s用力时间肺活量(FEV1)及第1 s用力时间肺活量/用力肺活量(FEV1/FVC)等肺功能指标水平。治疗前后,分别检测患者血清T细胞亚群(CD3~+、CD4~+及CD8~+)水平及免疫球蛋白(IgG、IgA及IgM)含量。观察所有患者毒副反应。结果观察组总有效率为84.2%,明显高于对照组(P0.05);治疗后,观察组DLCO、FEV1与FEV1/FVC等肺功能水平均明显高于对照组(P均0.05);观察组各项T细胞亚群及免疫球蛋白水平均明显高于对照组(P均0.05)。治疗期间所有患者均未发生严重不良反应,且观察组各项毒副反应发生率均明显低于对照组(P均0.05)。结论参蛤平喘胶囊可有效改善老年晚期非小细胞肺癌(NSCLC)合并COPD患者肺功能、血清T细胞亚群及免疫球蛋白水平,值得开展深入研究。

Clinical effects of Cangepingchuanjiaonang in the treatment of non-small cell lung cancer with chronic obstructive pulmonary disease in elderly patients

Objective To investigate the clinical effects of cangepingchuanjiaonang in the treatment of non-small cell lung cancer ( NSCLC) with Chronic obstructive pulmonary disease ( COPD) in elderly patients. Methods 114 elderly patients from Jan 2014 to Jan 2016 with advanced NSCLC with COPD in our hospital were randomly divided observation group and control group. The patients were treated with regular treatment, included oxygen, dilated bronchi and GP chemotherapy. The observation group was given cangepingchuanjiaonang on the base of control group. After treatment, the curative effects were evaluated. Before and after the treatment, the levels of DLCO, FEV1 , FEV1/FVC, CD3+, CD4+, CD8+, IgG, IgA and IgM were detected in the two groups. Then the toxicity of the two groups was compared. Results The total effective rate was 84.2％ in the observation group, significantly higher than the control group ( P<0.05) . After the treatment, the levels of DLCO, FEV1 , FEV1/FVC, CD3+, CD4+, CD8+, IgG, IgA and IgM were significantly higher in the observation group than which in the control group (P<0.05). During the treatment, there were no serious toxicity in the two groups and the rates of toxicity were significantly lower in the observation group than which in the control group (P<0.05). Conclusion Cangepingchuanjiaonang in the treatment of NSCLC with COPD in elderly patients has a good effect and worth to the next research.